Abstract
Background
Chronic inflammatory demyelinating polyradiculoneuropathy is a chronic progressive or relapsing and remitting disease with a prevalence of up to 8.9 per 100,000.
Methods
This review discusses possible mechanisms, none of which are proven, and describes the evidence for its treatment.
Results
Cochrane Reviews provide evidence that corticosteroids, intravenous immunoglobulin, and plasma exchange are effective short-term treatments. Attempts to confirm the efficacy of other immunosuppressant agents have not been successful, although they are often used in people whose disease is resistant to the first-line treatments.
Conclusions
More and better trials are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. Joint Task Force of the EFNS and the PNS: European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2005;10:220–8.
Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277:1–8.
Laughlin RS, Dyck PJ, Melton III LJ, Leibson C, Ransom J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45.
Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2006;11:30–46.
Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J Immunol. 2008;181:8753–60.
Yan WX, Archelos JJ, Hartung HP, Pollard JD. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:286–92.
Sanvito L, Makowska A, Mahdi-Rogers M, Hadden RD, Peakman M, Gregson N, et al. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2009;80:333–8.
Meléndez-Vásquez C, Redford J, Choudhary PP, Gray IA, Maitland P, Gregson NA, et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol. 1997;73:124–34.
Willison HJ. Ganglioside complexes: new autoantibody targets in Guillain-Barré syndromes. Nat Clin Pract Neurol. 2005;1:2–3.
Bosboom WM, Van den Berg LH, Mollee I, Sasker LD, Jansen J, Wokke JH, et al. Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology. 2001;56:74–81.
Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodrofe N, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain. 2002;125:823–34.
Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology. 1999;53:62–70.
Madia F, Frisullo G, Nociti V, Conti A, Luigetti M, Del Grande A, et al. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2009;14:107–17.
Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2008;13:54–63.
Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106:4788–92.
Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD002062, 2002.
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [update of Cochrane Database Syst Rev. 2002;(2):CD001797]. Cochrane Database Syst. Rev. CD001797, 2009.
Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD003906, 2004.
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. ICE Study Group: intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.
RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009;8:158–64.
Hughes R, Gorson K, Cros D, Griffin J, Pollard J, Vallat J-M, et al.: Efficacy of Interferon Beta-1a in patients with chronic inflammatory demyelinating polyneuropathy. Neurology. 2010;74: 651–7.
Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. CD003280, 2004.
Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77:544–7.
Conflict of Interest
Dr. Hughes has or has had consultancies with the following: Baxter, Biogen Idec, CSL Behring, Genzyme, Kedrion, LFB Group, Octapharma AG, and Talecris Biotherapeutics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hughes, R. Chronic Inflammatory Demyelinating Polyradiculoneuropathy. J Clin Immunol 30 (Suppl 1), 70–73 (2010). https://doi.org/10.1007/s10875-010-9399-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-010-9399-0